Media.Player

OsteoProtect

总结

Treatment of osteoporosis by inhibitors of sphingosine-1-phosphatase (S1P)-lyase.

技术优势

Novel approach for treating reduced bone density/stability
Specific inhibitors identified
In vivo data available

技术应用

Pharmacological therapy for osteoporotic fractures.

详细技术说明

The inventors showed that S1P inhibited osteoclast function, but most importantly, stimulated osteoblasts to produce new bone. Thus, a sufficient S1P-concentration is fundamental for an osteoanabolic fine-tuning of the skelettal system. Furthermore they showed that high S1P counteracts obesity by reducing adipose tissue mass. According to the invention, in patients suffering from osteoporosis, bone formation may be facilitated (and obesity reduced) by administering inhibitors of the S1P-lyase (the key enzyme degrading S1P). An exemplary S1P-lyase inhibitor tested by the inventors is the compound 4deoxypyridoxin (DOP).

合作类型

Licensing

申请日期

07/03/2019 00:00:00

申请号码

WO2019EP55667 20190307

分类

- international:
A61K31/417; A61K31/4415; A61K31/4439; A61P19/10; A61P3/06; A61P3/08
- cooperative:
A61K31/417 (EP); A61K31/4415 (EP); A61K31/4439 (EP); A61P19/10 (EP); A61P3/06 (EP); A61P3/08 (EP)

其他

Patent application

ID号码

4955

国家/地区

德国